{"id":"https://openalex.org/W4292177899","doi":"https://doi.org/10.1016/j.jval.2022.07.002","title":"Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase\u2013Positive Non\u2013Small Cell Lung Cancer","display_name":"Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase\u2013Positive Non\u2013Small Cell Lung Cancer","publication_year":2022,"publication_date":"2022-08-18","ids":{"openalex":"https://openalex.org/W4292177899","doi":"https://doi.org/10.1016/j.jval.2022.07.002","pmid":"https://pubmed.ncbi.nlm.nih.gov/35985941"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2022.07.002","doi":"https://doi.org/10.1016/j.jval.2022.07.002","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2022.07.002","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301522020988/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"http://www.valueinhealthjournal.com/article/S1098301522020988/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061242290","display_name":"Sarah C. Smith","orcid":"https://orcid.org/0000-0003-3380-4411","observed_orcids":["https://orcid.org/0000-0003-3380-4411"]},"institutions":[{"id":"https://openalex.org/I4210159506","display_name":"BresMed","ror":"https://ror.org/05fd45014","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210159506"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sarah Smith","raw_affiliation_strings":["BresMed Health Solutions, Sheffield, England, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BresMed Health Solutions, Sheffield, England, UK","institution_ids":["https://openalex.org/I4210159506"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088593783","display_name":"Fernando Albuquerque de Almeida","orcid":"https://orcid.org/0000-0001-8528-2702","observed_orcids":["https://orcid.org/0000-0001-8528-2702"]},"institutions":[{"id":"https://openalex.org/I4405254080","display_name":"Pfizer (Portugal)","ror":"https://ror.org/01ctjz153","country_code":"PT","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4405254080"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Fernando Albuquerque de Almeida","raw_affiliation_strings":["Pfizer Portugal, Porto Salvo, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Portugal, Porto Salvo, Portugal","institution_ids":["https://openalex.org/I4405254080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018492749","display_name":"M\u00f3nica Sofia In\u00eas","orcid":"https://orcid.org/0000-0003-3631-4995","observed_orcids":["https://orcid.org/0000-0003-3631-4995"]},"institutions":[{"id":"https://openalex.org/I4405254080","display_name":"Pfizer (Portugal)","ror":"https://ror.org/01ctjz153","country_code":"PT","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4405254080"]}],"countries":["PT"],"is_corresponding":true,"raw_author_name":"Monica In\u00eas","raw_affiliation_strings":["Pfizer Portugal, Porto Salvo, Portugal. Electronic address: monica.ines@pfizer.com","Pfizer Portugal, Porto Salvo, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Portugal, Porto Salvo, Portugal. Electronic address: monica.ines@pfizer.com","institution_ids":["https://openalex.org/I4405254080"]},{"raw_affiliation_string":"Pfizer Portugal, Porto Salvo, Portugal","institution_ids":["https://openalex.org/I4405254080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109611137","display_name":"Laura L. Iadeluca","orcid":"https://orcid.org/0000-0002-2379-6094","observed_orcids":["https://orcid.org/0000-0002-2379-6094"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Iadeluca","raw_affiliation_strings":["Pfizer Inc, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032736513","display_name":"Miranda Cooper","orcid":"https://orcid.org/0000-0001-8814-5500","observed_orcids":["https://orcid.org/0000-0001-8814-5500"]},"institutions":[{"id":"https://openalex.org/I4210159506","display_name":"BresMed","ror":"https://ror.org/05fd45014","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210159506"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Miranda Cooper","raw_affiliation_strings":["BresMed Health Solutions, Sheffield, England, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BresMed Health Solutions, Sheffield, England, UK","institution_ids":["https://openalex.org/I4210159506"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5018492749"],"corresponding_institution_ids":["https://openalex.org/I4405254080"],"apc_list":{"value":3200,"currency":"USD","value_usd":3200},"apc_paid":{"value":3200,"currency":"USD","value_usd":3200},"fwci":1.913,"has_fulltext":true,"cited_by_count":13,"citation_normalized_percentile":{"value":0.85387832,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"26","issue":"1","first_page":"64","last_page":"70"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lorlatinib","display_name":"lorlatinib","score":1.0},{"id":"https://openalex.org/keywords/anaplastic-lymphoma-kinase","display_name":"anaplastic lymphoma kinase","score":0.8700000047683716},{"id":"https://openalex.org/keywords/alk-positive-non-small-cell-lung-cancer","display_name":"ALK-positive non-small cell lung cancer","score":0.9890000224113464},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7760000228881836},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.6600000262260437},{"id":"https://openalex.org/keywords/platinum-based-chemotherapy","display_name":"platinum-based chemotherapy","score":0.996999979019165},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8870000243186951},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9980000257492065},{"id":"https://openalex.org/keywords/indirect-comparison","display_name":"indirect comparison","score":0.593999981880188},{"id":"https://openalex.org/keywords/evidence-synthesis","display_name":"evidence synthesis","score":0.42100000381469727}],"concepts":[{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.736390233039856},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7333291172981262},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.725168764591217},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6819983720779419},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.6810528635978699},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6721150279045105},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.6332516670227051},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5663389563560486},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5405731201171875},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4949423670768738},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.40485942363739014},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.0},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000068437","descriptor_name":"Pemetrexed","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077143","descriptor_name":"Docetaxel","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077548","descriptor_name":"Anaplastic Lymphoma Kinase","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007769","descriptor_name":"Lactams","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047029","descriptor_name":"Lactams, Macrocyclic","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.jval.2022.07.002","doi":"https://doi.org/10.1016/j.jval.2022.07.002","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2022.07.002","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301522020988/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},{"id":"pmid:35985941","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35985941","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","raw_type":"Systematic Review"}],"best_oa_location":{"id":"doi:10.1016/j.jval.2022.07.002","doi":"https://doi.org/10.1016/j.jval.2022.07.002","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2022.07.002","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301522020988/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4292177899.pdf","grobid_xml":"https://content.openalex.org/works/W4292177899.grobid-xml"},"referenced_works_count":16,"referenced_works":["https://openalex.org/W1505421350","https://openalex.org/W1982967337","https://openalex.org/W2004554806","https://openalex.org/W2092901728","https://openalex.org/W2111724182","https://openalex.org/W2415409512","https://openalex.org/W2623725180","https://openalex.org/W2741015391","https://openalex.org/W2780024648","https://openalex.org/W2796631032","https://openalex.org/W2888359589","https://openalex.org/W2899668190","https://openalex.org/W2905973807","https://openalex.org/W2982269583","https://openalex.org/W3164588837","https://openalex.org/W4210992155"],"related_works":["https://openalex.org/W3112680679","https://openalex.org/W2997692018","https://openalex.org/W4220777182","https://openalex.org/W3113143081","https://openalex.org/W4417317764","https://openalex.org/W2981855701","https://openalex.org/W4319333462","https://openalex.org/W3112803992","https://openalex.org/W4403002496","https://openalex.org/W3164588837"],"abstract_inverted_index":{"OBJECTIVES:":[0],"This":[1],"study":[2],"aimed":[3],"to":[4,65,180,208],"compare":[5],"the":[6,52,106,111,119,124,156,185,227],"relative":[7],"efficacy":[8],"of":[9,35,108,114,121,128,139,194,242],"lorlatinib,":[10],"an":[11,134,154],"anaplastic":[12,26],"lymphoma":[13,27],"kinase-tyrosine":[14],"kinase":[15],"inhibitor,":[16],"with":[17,21,101,150,173,200,222,245],"chemotherapy,":[18,223],"for":[19,47,71,159,171,175],"patients":[20],"second-line":[22],"or":[23,84,130],"later":[24],"advanced":[25],"kinase-positive":[28],"non-small":[29],"cell":[30],"lung":[31],"cancer.":[32],"The":[33,90,231],"endpoints":[34],"interest":[36],"were":[37,87,229],"overall":[38],"survival":[39,43],"(OS)":[40,196],"and":[41,68,80],"progression-free":[42],"(PFS).":[44],"METHODS:":[45],"Evidence":[46],"lorlatinib":[48,79,122,147,243],"was":[49,63,99,148,161,169,236],"informed":[50],"by":[51],"single-arm":[53],"phase":[54],"I/II":[55],"trial":[56],"B7461001.":[57],"A":[58],"systematic":[59],"literature":[60],"review":[61],"(SLR)":[62],"performed":[64,170],"identify":[66],"OS":[67,172,234],"PFS":[69,160,220],"data":[70],"chemotherapy.":[72],"Unanchored":[73],"matching-adjusted":[74],"indirect":[75],"comparisons":[76,235],"(MAICs)":[77],"between":[78],"chemotherapy":[81,115,152],"(pemetrexed/docetaxel,":[82],"platinum-based,":[83],"systemic":[85,176,198,246],"therapy)":[86],"performed.":[88],"RESULTS:":[89],"SLR":[91],"identified":[92,183],"3":[93],"relevant":[94],"studies":[95],"reporting":[96],"PFS.":[97],"Lorlatinib":[98,187,214],"associated":[100],"a":[102,189,216],"significant":[103,190,217],"decrease":[104,191],"in":[105,133,184,192,219,226],"hazard":[107,136,193],"progression":[109],"versus":[110,123,197],"2":[112],"types":[113],"assessed.":[116],"For":[117],"PFS,":[118],"MAIC":[120],"combined":[125],"treatment":[126],"arm":[127],"docetaxel":[129],"pemetrexed":[131],"resulted":[132],"adjusted":[135,157],"ratio":[137],"(HR)":[138],"0.22":[140],"(95%":[141,163,205,210],"confidence":[142],"interval":[143],"[CI]":[144],"0.15-0.31).":[145],"When":[146],"compared":[149,221,244],"platinum-based":[151],"through":[153],"MAIC,":[155],"HR":[158],"0.40":[162],"CI":[164,206,211],"0.29-0.55).":[165],"An":[166],"exploratory":[167],"comparison":[168],"evidence":[174,232],"therapy":[177],"(assumed":[178],"equivalent":[179],"chemotherapy)":[181],"not":[182],"SLR.":[186],"provided":[188],"death":[195],"therapy,":[199],"HRs":[201],"ranging":[202],"from":[203],"0.12":[204],"0.05-0.27)":[207],"0.43":[209],"0.27-0.60).":[212],"CONCLUSIONS:":[213],"demonstrated":[215],"improvement":[218],"although":[224],"limitations":[225],"analyses":[228],"identified.":[230],"informing":[233],"highly":[237],"limited":[238],"but":[239],"suggested":[240],"benefit":[241],"therapy.":[247]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2022-08-18T00:00:00"}